SCHEMBL2734591

SCHEMBL2734591

COc1ccc(O)cc1CN1CCNCC1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.61
CHRM2 P08172 1/20 0.61
SLC6A4 P31645 1/20 0.61
OPRD1 P41143 1/20 0.61
OPRK1 P41145 1/20 0.61
APOBEC3A P31941 1/20 0.59
CTDSP1 Q9GZU7 1/20 0.59
APOBEC3G Q9HC16 1/20 0.59
KDM4E B2RXH2 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
GNAI3 P08754 1/20 0.49
USP2 O75604 1/20 0.49
CYP2D6 P10635 1/20 0.49
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3381031 0.86 KDM4E (0.66) KDM4ETDP1LMNAMAPTL3MBTL1
SCHEMBL1714907 0.84 SLC6A4 (0.62) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL7300721 0.84 CYP1A2 (0.62) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL9185135 0.81 CYP1A2 (0.59) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL1714117 0.80 SLC6A4 (0.58) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL18023359 0.80 L3MBTL1 (0.58) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL29953174 0.79 CYP1A2 (0.57) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL591547 0.78 CYP2D6 (0.74) CYP1A2CHRM2SLC6A4OPRD1OPRK1
Hydrochloric Acid SCHEMBL27837634 0.78 KDM4E (0.63) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL8064097 0.78 CHRM2 (0.76) CYP1A2CHRM2SLC6A4OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD CYP1A2 332/4885CHRM2 3382/4885SLC6A4 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.